NEW YORK, June 18 /PRNewswire-FirstCall/ -- Medicsight PLC (AIM: MDST), a subsidiary of MGT Capital Investments, Inc. (the "Company"), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announced that data presented at the recent European Society of Gastrointestinal and Abdominal Radiology (ESGAR) in Istanbul showed that the use of the Medicsight Computer-Aided Detection (CAD) helped radiographers to detect 100% of cancers when examining more than 300 patients in routine primary reporting of virtual colonoscopy (VC).
"These findings are exciting because whilst demand for colorectal cancer investigation is on the rise, there is a shortage of radiologists trained to report VC in many countries," said Dr David Burling, Consultant Radiologist from St Mark's Hospital, London. "If radiographers can be trained to interpret scans more effectively using CAD technology, both radiology teams and patients will benefit, with the ultimate goal of decreasing the incidence and morbidity of colorectal cancer, the second most common cause of death from cancer in Europe."
In the study, 304 patients (61% female) underwent VC as part of routine clinical care. Examinations were read by two trained radiographers supplemented by CAD as a 'second reader'. Radiographers recorded colonic abnormalities and interpretation times and proposed one of six different codes for each examination (Categories S0-5: inadequate/normal/6-9 mm polyp/10mm+ polyp/cancer/diverticular stricture). Findings were compared to that of an experienced radiologist and supplemented by colonoscopic findings if available.
The radiographers, assisted by CAD detected 100% (17/17) of cancers; 72% (21/29) of 10 mm+ polyps and 67% (42/63) of 6-9 mm polyps. Overall agreement between radiographer and radiologist examinations was good, demonstrating that use of CAD by trained radiographers provides an effective triage strategy in initial patient management following VC. Notably on retrospective analysis, CAD had actually detected 60% of polyps missed by radiographers. Therefore, had radiographers accepted these correct CAD annotations, their detection rates would have been 83% and 89% for medium and large polyps respectively.
David Sumner, CEO of Medicsight commented, "This study is yet another positive validated outcome for Medicsight ColonCAD. It further confirms the CAD's accuracy in a user group (Radiographers) that will play a vital role in any colorectal screening programme being implemented in the world today."
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.
Medicsight PLC (AIM: MDST) is a leading developer of computer-aided detection (CAD) software solutions. Medicsight's CAD solutions help clinicians utilizing Computed Tomography (CT) scans to identify, measure and analyze suspicious pathology within the colon and lungs. The Medicsight CAD products are validated against one of the world's largest databases of verified CT scan data collected from leading healthcare institutions from around the world. Medicsight products allow radiologists and physicians to review scans more quickly and accurately -- saving both time and lives
Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.
Additional information can be found at www.mgtci.com.
All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
CONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or Garth Russell,
+1-212-896-1250, grussell@kcsa.com, both of KCSA Strategic Communications,
for MGT Capital Investments
Web site: http://www.mgtci.com/